What is XELJANZ®?
What is XELJANZ®?1
- XELJANZ® contains the active ingredient tofacitinib1
- XELJANZ® is the first-in-class of a new oral treatment that targets the Janus kinase (JAK) pathways2
- Excessive production of cytokines causes joint pain and symptoms through activation of the JAK pathways2
How to take XELJANZ®?
How to take XELJANZ®?1

Efficacy of XELJANZ®
Efficacy of XELJANZ®
An oral JAK inhibitor proven to deliver a powerful, rapid relief of joint pain caused by autoimmunity3
START FIRST WITH XELJANZ®

STAY WITH XELJANZ®

Safety of XELJANZ®
XELJANZ® offers a consistent safety profile
Consistent safety data with
Consistent safety profile
The safety profile of XELJANZ® is consistent either as monotherapy or combination therapy8No increase in selected adverse events
No significant increases in incidence rates (IR) of selected adverse events over 78 months*8* Please consult your doctor or your pharmacist for more information.